CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 CAR-T 细胞治疗复发/难治性弥漫大 B 细胞淋巴瘤：为何失败？
英文原题：CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
查看英文原题
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞疗法是治疗复发/难治性弥漫性大B细胞淋巴瘤（DLBCL）的有效方法，目前已有3种靶向CD19的产品获FDA批准用于该适应症。然而，高达60%的患者在CAR-T 细胞治疗后最终出现疾病进展或复发。DLBCL患者对CAR-T 细胞疗法耐药的机制可能是多因素的，尚未完全阐明。确定可能预测个体对CAR-T 细胞治疗反应的患者、肿瘤和治疗相关因素，需要对该人群的临床试验数据和真实世界经验进行持续分析。在这篇综述中，我们将讨论迄今为止已确定的可能导致DLBCL患者CAR-T 细胞疗法未能实现持久缓解的因素。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed or refractory diffuse large B cell lymphoma (DLBCL) with 3 CD19 targeting products now FDA-approved for this indication.
However, up to 60% of patients ultimately progress or relapse following CAR-T cell therapy. Mechanisms of resistance to CAR-T cell therapy in patients with DLBCL are likely multifactorial and have yet to be fully elucidated.
Determining patient, tumor and therapy-related factors that may predict an individual's response to CAR-T cell therapy requires ongoing analysis of data from clinical trials and real-world experience in this population. In this review we will discuss the factors identified to-date that may contribute to failure of CAR-T cell therapy in achieving durable remissions in patients with DLBCL.
论文信息
- 作者
- Kinoshita H、Bollard CM、Toner K
- 单位
- Cell Enhancement and Technologies for Immunotherapy, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University, Washington, DC.
- 文献类型
- 综述 · 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Seminars in hematology2023 Nov
- 原文标识
- PubMed 38336529 · DOI 10.1053/j.seminhematol.2023.11.007
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →